# Exai Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/exai-bio

- Industry: Biotechnology
- Headquarters: Palo Alto, US
- Website: https://exai.bio
- Total disclosed funding: $68M
- Latest round: Series A (Dec 9, 2021)
- Investors on record: 3

## About

Based in California, US, and founded in 2021, Exai Bio Inc. operates as a liquid biopsy company. Patrick Arensdorf (CEO) and Babak Alipanahi (Chief Scientific Officer) and Hani Goodarzi are the co-founders of the company. In December 2021, Exai Bio Inc. raised USD 67.5 million in series A funding, co-led by new investors Section 32 and Casdin Capital, with participation from another new investor, Two Sigma Ventures.

The company's platform provides clinical insight into cancer biology from non-invasive blood samples, allowing for early cancer detection and individualized treatment. Exai Bio's patented platform measures cell-free RNA profiles and analyses them with artificial intelligence and machine learning algorithms. It focuses on orphan non-coding RNA (oncRNA), which are short RNA sequences seen in malignancies but not in normal tissue.

The company plans to use the series A funding received in December 2021 to accelerate the development of its non-invasive, RNA-based liquid biopsy platform for early cancer detection.

## Funding rounds

- Series A, Dec 9, 2021, $68M — Two Sigma Investments, Casdin Capital, Section 32

## Investors

- Two Sigma Investments (https://capitalatlas.ai/funds/two-sigma-investments) — Series A
- Casdin Capital (https://capitalatlas.ai/funds/casdin-capital) — Series A
- Section 32 (https://capitalatlas.ai/funds/section-32) — Series A